Advisory Services Network LLC Grows Stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Advisory Services Network LLC boosted its position in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 60.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 40,656 shares of the company’s stock after purchasing an additional 15,353 shares during the quarter. Advisory Services Network LLC’s holdings in Teva Pharmaceutical Industries were worth $896,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of TEVA. Stifel Financial Corp boosted its position in shares of Teva Pharmaceutical Industries by 54.0% in the 3rd quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock worth $1,196,000 after buying an additional 23,283 shares in the last quarter. Robeco Institutional Asset Management B.V. lifted its holdings in shares of Teva Pharmaceutical Industries by 7.2% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 498,309 shares of the company’s stock valued at $10,983,000 after purchasing an additional 33,277 shares in the last quarter. Pinnbrook Capital Management LP acquired a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter valued at approximately $4,966,000. Asset Management One Co. Ltd. increased its stake in shares of Teva Pharmaceutical Industries by 14.6% during the 4th quarter. Asset Management One Co. Ltd. now owns 457,371 shares of the company’s stock worth $10,414,000 after purchasing an additional 58,413 shares in the last quarter. Finally, CWA Asset Management Group LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 4th quarter worth approximately $3,340,000. Institutional investors and hedge funds own 54.05% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Piper Sandler raised their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research report on Friday, January 17th. UBS Group dropped their price objective on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. Bank of America reduced their target price on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, March 6th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Friday, April 4th. Finally, Barclays reduced their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, January 30th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, Teva Pharmaceutical Industries has a consensus rating of “Moderate Buy” and an average price target of $23.43.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock opened at $13.42 on Monday. Teva Pharmaceutical Industries Limited has a 1 year low of $12.47 and a 1 year high of $22.80. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. The firm has a 50 day moving average price of $15.79 and a 200 day moving average price of $17.82. The company has a market cap of $15.22 billion, a price-to-earnings ratio of -9.26, a PEG ratio of 1.44 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA) last issued its earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. Sell-side analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.